Page 10 - கிஂட்ரிட் உயிர் அறிவியல் இன்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kindred Biosciences Announces First Quarter 2021 Financial Results News provided by Share this article Share this article SAN FRANCISCO, May 11, 2021 /PRNewswire/  Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2021 and provided updates on its programs. For the first quarter 2021, KindredBio reported net revenues of $2.4 million and a net loss of $9.7 million, or $0.24 per share. We had a strong start to the year, announcing positive results in a new long-acting interleukin-31 antibody program that has the potential to become a best-in-class therapeutic, alongside the acceptance of efficacy data for our parvovirus monoclonal antibody program. With cash runway now through the end of 2023, we are well-positioned to realize the value of our promising late-stage pipeline, said KindredBio s Chief Executive Officer, Richard Chin, M.D.

United statesKatja buhrerRichard chinKindred biosciences incDrug administrationElanco animal healthMirataz to dechra pharmaceuticalsDechra pharmaceuticalsExchange commissionUnited states department of agriculture centerUnited states department of agricultureKindred biosciencesChief executive officerUnited states departmentElanco animalSecurities litigation reform act